Who is at Risk? Lessons Learned
Journal: Haematology International Journal (HIJ) (Vol.4, No. 2)Publication Date: 2020-07-03
Abstract
A young man walked into my office for fatigue and thrombocytopenia, a common disease Hematologists see of low platelets. A recent article from California talked of an unusual disease not seen often in non-immunocompromised patients. No cause was apparent. Soon there were several reports with a similar clinical picture in other risks groups. Within a short time a causative agent was found. Early diagnostic tests had been developed and took some time to be standardized. Rapid deaths occurred in about 50% of affected persons, with life expectancy of one year. Within four years the first effective drug was licensed by the FDA. Many global attempts at a vaccine had failed. This was initially known as the syndrome AIDS, until the virus was identified as HIV, human immunodeficiency virus.
Other Latest Articles
- Haemovigilance Fact and Fiction
- Evaluation of Soluble Intercellular Adhesion Molecule-1 and Soluble P Selection in Sickle Cell Disease
- COVID19 War, Triangle with Inflammation and Infection
- Compound Heterozygous Sickle Cell and Beta Thalessemia Trait with High Hb F: A Rare Case from India
- Current Trend in Blood Transfusion Science, Where are we?
Last modified: 2022-09-12 18:11:59